Clinical and economic impact of a combination Haemophilus influenzae and hepatitis B vaccine: Estimating cost-effectiveness using decision analysis

Archives of Pediatrics and Adolescent Medicine

Volumn 153, Issue 2, 1999, Pages 126-136

  Fendrick, A Mark ^a,b,d   Lee, Jason H ^b   LaBarge, Cory ^c   Glick, Henry A ^b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE;

ARTICLE; BACTERIAL INFECTION; CHILDHOOD DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; TREATMENT OUTCOME; VACCINATION;

ADOLESCENT; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MALE; MARKOV CHAINS; MENINGITIS, HAEMOPHILUS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); UNITED STATES;

EID: 0032907253     PISSN: 10724710     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (105)

1. Woodin KA, Rodewald LE, Humiston SG, Carges MS, Schaffer SJ, Szilagyi PG. Physician and parent opinions: are children becoming pincushions from immunizations? Arch Pediatr Adolesc Med. 1995;149:845-849.
2. Halsey NA. Practical considerations regarding the impact on immunization schedules of the introduction of new combined vaccines. Ann N Y Acad Sci. 1995; 754:250-254.
3. West DJ, Calandra GB, Hesley TM, Ioli V, Miller WJ. Control of hepatitis B through routine immunization of infants: the need for flexible schedules and new combination vaccine formulations. Vaccine. 1993;11(suppl 1):S21-S27.
4. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19-35 months: United States, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:963-969.
5. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep. 1991;40 (RR-13):1-19.
6. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA. 1995;274:1201-1208.
7. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med. 1993;118:298-306.
8. Krahn M. Detsky AS. Should Canada and the United States universally vaccinate infants against hepatitis B? a cost-effectiveness analysis. Med Decis Making. 1993;13:4-20.
9. Arevalo JA. Washington AE. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus [published correction appears in JAMA. 1988; 260:478]. JAMA. 1988;259:365-369.
10. Arevalo JA. Washington AE. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus [published correction appears in JAMA. 1988; 260:478]. JAMA. 1988;259:365-369.
11. Mulley AG, Silverstein MD, Dienstag JL. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med. 1982;307:644-652.
12. Centers for Disease Control and Prevention. FDA approval for infants of a Haemophilus influenzae type b conjugate and hepatitis B (recombinant) combined vaccine. MMWR Morb Mortal Wkly Rep. 1997;46:107-109.
13. Miller MA, Sutter RW. Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA. 1996;276:967-971.
14. Beck JR, Pauker SG. The Markov process in medical decision making. Med Decis Making. 1983;3:419-458.
15. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
16. Centers for Disease Control and Prevention. Maternal hepatitis B screening practices: California. Connecticut. Kansas, and United States. 1992-1993. MMWR Morb Mortal Wkly Rep. 1994;43:311-320.
17. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977;105:94-98.
18. Stevens CE, Neurath RA, Beasley RP, Szmuness W. HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol. 1979;3:237-241.
19. Sehgal A, Gupta I, Sehgal R, Ganguly NK. Hepatitis B vaccine alone or in combination with anti-HBs immunoglobulin in the perinatal prophylaxis of babies born to HBsAg carrier mothers. Acta Virol. 1992;36:359-366.
20. Wong VCW, Ip HMH, Reesink HW. et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Lancer. 1984;1:921-926.
21. Beasley RP, Hwang L-Y, Lee GC-Y, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2:1099-1102.
22. Francis DP, Hadler SC, Prendergast TJ, et al. Occurrence of hepatitis A, B, and non-A/non-B in the United States: CDC Sentinal County Hepatitis Study 1. Am J Med. 1984;76:69-74.
23. Centers for Disease Control and Prevention. Hepatitis Surveillance Report No 54. Atlanta. Ga: Centers for Disease Control and Prevention; 1992.
24. Kumar ML, Dawson NV, McCullough AJ, et al. Should all pregnant women be screeened for hepatitis B? Ann Intern Med. 1987;107:273-277.
25. Cruz AC, Frentzen BH, Behnke M. Hepatitis B: a case for prenatal screening of all patients. Am J Obstet Gynecol. 1987;156:1180-1183.
26. Ernest JM, Givner LB, Pool R. Intrapartum hepatitis B screening in a low-risk population. Am J Obstet Gynecol. 1990;163:978-980.
27. Shah N, Ostrow D, Altman N, Baker AL. Evolution of acute hepatitis B in homosexual men to chronic hepatitis B: prospective study of placebo recipients in a hepatitis B vaccine trial. Arch Intern Med. 1985;145:881-882.
28. Schweitzer IL. Vertical transmission of the hepatitis B surface antigen. Am J Med Sci. 1975;270:287-291.
29. Redeker AG. Viral hepatitis: clinical aspects. Am J Med Sci. 1975;270:9-16.
30. McMahon BJ, Alward WLM, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151:599-603.
31. Shapiro CN. Epidemiology of hepatitis B. Pediatr Infect Dis J. 1993;12:433-437.
32. Pearce N, Milne A, Moyes C. Hepatitis B virus: the importance of age at infection. N Z Med J. 1988;101:788-790.
33. Tassopoulos NC, Papaevangelou GJ, Sjogren MH. Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology. 1987;92:1844-1850.
34. Karvountzis GG, Redeker AG, Peters RL. Long term follow-up studies of patients surviving fulminant viral hepatitis. Gastroenterology. 1974;67:870-877.
35. Dupuy JM, Frommel D, Alagille D. Severe viral hepatitis type B in infancy. Lancet. 1975;1:191-194.
36. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae: prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med. 1990;150:1051-1054.
37. de Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993;118:191-194.
38. Alward WL, McMahon BJ, Hall DB, Heyward WL, Francis DP, Bender TR. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis. 1985;151:604-609.
39. Liaw Y-F, Tai D-I, Chu C-M, Chen T-J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8:493-496.
40. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991;32:294-298.
41. Weissberg JI, Andres LL, Smith CI, et al. Survival in chronic hepatitis B: an analysis of 379 patients. Ann Intern Med. 1984;101:613-616.
42. Lo K-J, Tong M-J, Chien M-C, etal. The natural history of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan. J Infect Dis. 1982;146:205-210.
43. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med. 1993;119:312-323.
44. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 1993;269:221-226.
45. Shinefield HR, Black S. Postlicensure surveillance for Haemophilus influenzae type b invasive disease after use of Haemophilus influenzae type b oligosaccharide CRM197 conjugate vaccine in a large defined United States population: a four-year eight-month follow-up. Pediatr Infect Dis J. 1995;14:978-981.
46. Redmond SR, Pichichero ME. Hemophilus influenzae type b disease: an epidemiologic study with special reference to day-care centers. JAMA. 1984;252: 2581-2584.
47. Nesheim SR, Wilcox WD. Systemic Hemophilus influenzae disease in children: a 10-year retrospective study of an urban hospital population. Clin Pediatr (Phila). 1986;25:605-609.
48. Dajani AS, Asmar BI. Thirumoorthi MC. Systemic Haemophilus influenzae disease: an overview. J Pediatr. 1979;94:355-364.
49. Gilbert GL, Johnson PDR, Clements DA. Clinical manifestations and outcome of Haemophilus influenzae type b disease. J Paediatr Child Health. 1995;31:99-104.
50. Ward JI, Lum MKW, Hall DB, Silimperi DR, Bender TR. Invasive Haemophilus influenzae type b disease in Alaska: background epidemiology for a vaccine efficacy trial. J Infect Dis. 1986;153:17-26.
51. Gilbert GL. Epidemiology of Haemophilus influenzae type b disease in Australia and New Zealand. Vaccine. 1991;9(suppl):S10-S13.
52. Anderson EC, Begg NT, Crawshaw SC, Hargreaves RM, Howard AJ, Slack MPE, Epidemiology of invasive Haemophilus influenzae infections in England and Wales in the pre-vaccination era (1990-1992). Epidemiol Infect. 1995;115:89-100.
53. Schoendorf KC, Adams WG, Kiely JL, Wenger JD. National trends in Haemophilus influenzae meningitis mortality and nospitalization among children, 1980 through 1991. Pediatrics. 1994;93:663-668.
54. Schlech WF III, Ward JI, Band JD, Hightower A, Fraser DW, Broome CV. Bacterial meningitis in the United States. 1978 through 1981: The National Bacterial Meningitis Surveillance Study. JAMA. 1985;253:1749-1754.
55. McIntyre P, Jepson R, Leeder S, Irwig L. The outcome of childhood Haemophilus influenzae meningitis: a population based study. Med J Aust. 1993;159:766-772.
56. Senior BA, Radkowski D, MacArthur C, Sprecher RC, Jones D. Changing patterns in pediatric supraglottitis: a multi-institutional review. 1980 to 1992. Laryngoscope. 1994;104(11, pt 1):1314-1322.
57. Emmerson SGP, Richman B, Spahn T. Changing patterns of epiglottitis in children. Otolaryngol Head Neck Surg. 1991;104:287-292.
58. Molteni RA. Epiglottitis: incidence of extraepiglottic infection: report of 72 cases and review of the literature. Pediatrics. 1976;58:526-531.
59. Herson VC, Todd JK. Prediction of morbidity in Hemophilus influenzae meningitis. Pediatrics. 1977;59:35-39.
60. D'Angio CT, Froehlke RG, Plank DJ, et al. Long-term outcome of Haemophilus ifluenzae meningitis in Navajo Indian children. Arch Pediatr Adolesc Med. 1995; 149:1001-1008.
61. Lindberg J, Rosenhall U, Nylen O, Ringner A. Long-term outcome of Haemophilus influenzae meningitis related to antibiotic treatment. Pediatrics. 1977;60: 1-6.
62. Bower C, Payne J, Condon R, Hendrie D, Harris A, Henderson R. Sequelae of Haemophilus influenzae typt b meningitis in Aboriginal and non-Aboriginal children under 5 years of age. J Paediatr Child Health. 1994;30:393-397.
63. Letson GW, Gellin BG, Bulkow LR, Parks DJ, Ward JI. Severity and frequency of sequelae of bacterial meningitis in Alaska Native infants: correlation with a scoring system for severity of sequelae. AJDC. 1992;146:560-566.
64. Sell SHW, Merril RE, Doyne EG, Zinksy EP. Long-term sequelae of Hemophilus influenzae meningitis. Pediatrics. 1972;49:206-211.
65. Evans RW, Manninen DL, Dong FB. An economic analysis of liver transplantation: costs, insurance coverage, and reimbursement. Gastroenterol Clin North Am. 1993;22:451-473.
66. Payne JL, McCarty KR, Drougas JG, et al. Outcomes analysis for 50 liver transplant recipients: the Vanderbilt experience. Am Surg. 1996;62:320-325.
67. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-α2b treatment tor hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med. 1995; 122:564-675.
68. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology. 1995;22:1863-1873.
69. Hay JW, Daum RS. Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection. Pediatrics. 1987;80:319-329.
70. Fujiura GT, Roccoforte JA, Braddock D. Costs of family care for adults with mental retardation and related developmental disabilities. Am J Mental Retard. 1994; 99:250-261.
71. Cochi SL, Broome CV, Hightower AW. Immunization of US children with Haemophilus influenzae type b polysaccharide vaccine: a cost-effectiveness model of strategy assessment. JAMA. 1985;253:521-529.
72. Centers for Disease Control and Prevention (US). CDC Vaccine Price List. Atlanta. Ga: Centers for Disease Control and Prevention: March 1997.
73. McManon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43 618 persons. Am J Med. 1992;92:254-256.
74. Duclos P, for the Bureau of Communicable Disease Epidemiology. Adverse events after hepatitis B vaccination. CMAJ. 1992;147:1023-1026.
75. Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Infect Dis J. 1993;12:438-445.
76. Alter MJ, Mares A, Halder SC, Maynard JE. The effect ot underreporting on the apparent incidence and epidemiology of acute viral hepatitis. Am J Epidemiol. 1987;125:133-139.
77. de Jongh FE, Janssen HLA, de Man RA, Hop WCJ, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology. 1992;103:1630-1635.
78. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993;18:47-53.
79. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicentric study. J Hepatol. 1994;21:656-666.
80. Salerno F, Borroni G, Moser P, et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol. 1993;88:514-519.
81. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842-1847.
82. Gonzalez EM, Loinaz C, Garcia I, et al. Liver transplantation in chronic viral B and C hepatitis. J Hepatol. 1993;17(suppl 3):S116-S122.
83. Buscarini L, Fornari F, Canaletti R, et al. Diagnostic aspects and follow-up of 174 cases of hepatocellular carcinoma: second report. Oncology. 1991;48:26-30.
84. Calvet X, Bruix J, Bru C, et al. Natural history ot hepatocellular carcinoma in Spain: five year's experience in 249 cases. J Hepatol. 1990;10:311-317.
85. Harris A, Hendrie D, Bower C, Payne J, de Klerk N, Stanley F. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of PRP-OMP in Australia. Med J Aust. 1995;160:483-488.
86. O'Brien KF, Tate K, Zaharia ES. Mortality in a large southeastern facility for persons with mental retardation. Am J Mental Retard. 1991;95:397-403.
87. Simila S, von Wendt L, Rantakallio P. Mortality of mentally retarded children to 17 years of age assessed in a prospective one-year birth cohort. J Ment Defic Res. 1986;30:401-405.
88. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA. 1987;257:2612-2616.
89. Poovorawan Y, Sanpavat S, Pongpunglert W, et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J. 1992;11:816-821.
90. Lee C-Y, Huang L-M, Chang M-W, et al. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J. 1991;10:299-303.
91. Tan KL, Oon CJ, Goh KT, Wong LYM, Chan SH. Immunogenicity and safety of low doses of recombinant yeast-derived hepatitis B vaccine. Acta Paediatr Scand. 1990;79:593-598.
92. Hadler SC, Margolis HS. Hepatitis B immunization: vaccine types, efficacy and indications for immunization. Curr Clin Trop Infect Dis. 1992;12:282-308.
93. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect. 1986;13(suppl A):39-45.
94. Marion SA, Pastore MT, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol. 1994;140:734-746.
95. Milne A, Krugman S, Waldon JA, et al. Hepatitis B vaccination in children: five year booster study. N Z Med J. 1992;105:336-338.
96. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med. 1982;97:362-366.
97. Merck & Co. ComVax: Haemophilus b conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine [prescribing information]. West Point. Pa: Merck & Co Inc; 1996.
98. Harrison LH, Tajkowski C, Croll J, et al. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children. J Pediatr. 1994;125:571-576.
99. Vadheim CM, Greenberg DP, Eriksen E, et al. Protection provided by Haemophilus influenzae type b conjugate vaccines in Los Angeles County: a case-control study. Pediatr Infect Dis J. 1994;13:274-280.
100. Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation. 1992;85:1960-1968.
101. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press: 1996.
102. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med. 1991;324:1362-1365.
103. Freed GL, Bordley WC, Clark SJ, Konrad TR. Family physician acceptance of universal hepatitis B immunization of infants. J Fam Pract. 1993;36:153-157.
104. Melman ST, Chawla T, Kaplan JM, Anbar RD. Multiple immunizations: ouch! Arch Fam Med. 1994;3:615-618.
105. Centers for Disease Control and Prevention. Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine. MMWR Morb Mortal Wkly Rep. 1993;42(RR-13):1-15.